Peter C.C. Fong

Also affiliated with Auckland City Hospital, Auckland District Health Board

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers”.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

New England Journal of Medicine(2009)10.1056/nejmoa0900212

N/A

1.2DataRank · unranked

3622 citations

David S. Boss, Timothy A. Yap, Richard Turkington, Peijun Wu, Marja Mergui-Roelvink +14 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

The impact of coding germline variants on contralateral breast cancer risk and survival

The American Journal of Human Genetics(2023)10.1016/j.ajhg.2023.02.003

N/A

0.500DataRank · unranked

27 citations

Nasim Mavaddat, Taru Muranen, Thomas U. Ahearn, Jamie Allen, Irene L. Andrulis +94 more

Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset

The American Journal of Human Genetics(2024)10.1016/j.ajhg.2024.07.004

N/A

0.330DataRank · unranked

8 citations

Kyriaki Michailidou, Michael T. Parsons, Cristina Fortuño, Manjeet K. Bolla, Qin Wang +95 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more